German Equivalent of US Drugs: A Professional Guide

To find the German equivalent of a US medicinal product, work from the active substance and its ATC code, never from the brand name. The reliable professional route is US brand to active substance to INN to ATC code to German authorised products, then down to the individual package identified by its PZN, with strength, dosage form, pack size and authorisation status checked at each step. Brand name lookups fail because brands are assigned nationally by different marketing authorisation holders and carry no guarantee of substance identity across markets.

This is a routine task in clinical trial supply, hospital pharmacy procurement, parallel import sourcing, regulatory dossier work and medical information. It is also routinely underestimated. The following sets out why brand mapping breaks, what the reliable method is, where the traps sit, and what a defensible workflow looks like.

Why brand names do not map across markets

A brand name is a national commercial asset, not an identifier of substance. The same active substance is marketed in Germany and the United States under different brand names, by different companies, because marketing authorisations, trademark rights and distribution agreements are territorial. There is no global brand register that guarantees one-to-one correspondence.

The harder problem runs in the other direction. The same brand name can denote different active substances in different countries. The World Health Organization has flagged this explicitly in its patient safety work on medication names, noting that medicines marketed under the same or similar sounding brand names may contain different active ingredients in different countries. That is not an edge case in cross-border work, it is a foreseeable hazard, and it is why a brand-to-brand mapping table is not an acceptable professional artefact.

"Some medicines, although marketed under the same or similar sounding brand names, may contain different active ingredients in different countries." World Health Organization, Patient Safety Solutions, Look-Alike, Sound-Alike Medication Names

The data-integrity consequence follows directly. Any system that resolves a cross-border query on brand string similarity is producing plausible answers with no basis in substance identity.

The reliable method: active substance and ATC code

The stable layer is the active substance, and the stable classification of that substance is the Anatomical Therapeutic Chemical (ATC) classification, maintained by the WHO Collaborating Centre for Drug Statistics Methodology in Oslo. The ATC system sorts active substances into fourteen anatomical main groups and five hierarchical levels.

Two properties make the ATC code the right pivot for cross-border mapping. It is assigned to the substance, not to the pack or the brand, so it survives every commercial difference between markets. And when the exact substance has no authorised German counterpart, moving one level up the hierarchy gives a defensible set of therapeutic alternatives rather than a guess.

One limitation must be stated plainly, because it is where inexperienced users go wrong: a medicinal product with two or more active substances usually receives a single ATC code for the combination rather than the codes of its components, and a substance used at clearly different doses for clearly different indications can carry more than one code. ATC is a classification for drug utilisation statistics. It is an excellent pivot, not a substitute for reading the authorised product information.

INN, USAN and national naming

Even the substance name is not automatically the same on both sides. The International Nonproprietary Name (INN) programme run by the WHO assigns a single globally recognised name to each pharmaceutical substance. The United States maintains its own scheme, the United States Adopted Name (USAN). The two agree for the large majority of substances, but not for all of them, and the divergences cluster in exactly the high-volume substances a cross-border query is most likely to involve.

Add a third layer on top: German product information and everyday German professional usage apply German orthography and, in older or traditional products, German substance designations that match neither INN nor USAN spelling. A literal string search on a US substance name against a German dataset will therefore return nothing for a substance that is in fact widely authorised in Germany. The practical rule is to normalise to the INN first, then search, and to treat any zero-result search as a naming question before treating it as an availability answer.

Strength, dosage form and pack size

Once the substance matches, the product still may not. Three attributes routinely diverge between a US product and its nearest German counterpart:

• Strength. Authorised strengths differ between markets, and a strength that is standard in one country may not be authorised at all in the other.
• Dosage form. Modified release, immediate release, film-coated, orodispersible and parenteral presentations are separate products with separate authorisations. Two products sharing an ATC code and a strength are not interchangeable if the release characteristics differ.
• Pack size. Germany additionally uses the standardised N1, N2 and N3 pack size categories in the prescription context, which have no US counterpart.

The word "equivalent" is doing a lot of work here, and it needs to be resolved before the search starts. Same substance, same substance and strength, same substance and pharmaceutical form, therapeutically comparable, and formally substitutable are five different questions with five different answer sets. State which one is being asked, in the query and in the deliverable.

Authorisation status differences

A substance authorised in the United States may be unauthorised in Germany, authorised for a narrower or wider indication, authorised under different prescribing restrictions, or withdrawn from the market. The reverse holds as well. Regulatory decisions are made independently by the FDA on one side and, on the other, by the European Medicines Agency for centrally authorised products or by the national competent authority for nationally authorised ones.

Withdrawal adds a temporal dimension. A German product may exist in historical data, may still be authorised but no longer marketed, or may be temporarily unavailable because of a supply shortage. Those three states have very different operational meanings, and a dataset that collapses them into "not found" is unusable for procurement or trial supply. Authorisation status, marketing status and current availability are three separate fields and must be read as three separate fields.

The practical professional workflow

The defensible sequence is short and each step is checkable:

1. Resolve the US brand to its active substance. Take the substance from the US product information, not from a secondary list.
2. Normalise the substance name to the INN. Explicitly check the known USAN divergences before concluding that a substance is absent from German data.
3. Obtain the ATC code. This becomes the pivot for everything that follows.
4. Retrieve German authorised products under that ATC code. Expect several marketing authorisation holders and several brands per substance.
5. Filter by strength, dosage form and pharmaceutical presentation against the definition of equivalence you fixed at the start.
6. Resolve down to the PZN. The PZN identifies one specific package, which is the level at which ordering, pricing and reimbursement actually happen.
7. Check marketing status, availability and price at that PZN, including any current supply shortage.
8. Document the chain. Substance, INN, ATC, product, PZN, date of retrieval. Regulatory and clinical work is audited, and an undocumented mapping cannot be defended later.

If step 4 returns nothing, do not stop. Move one ATC level up to identify therapeutic alternatives, and record explicitly that the answer is an alternative rather than an equivalent.

Where this work actually arises

Five professional contexts generate the bulk of these queries, and each puts a different weight on the same chain:

Common to all five is that the answer is worthless without the substance identity being airtight, and slow without the country coverage being in one place.

Four failure modes to design against

The same four errors account for most defective cross-border mappings, and all four are avoidable at the point where the query is written rather than at the point where it is reviewed.

• Treating a zero result as an absence. A search that returns nothing far more often means the substance name was not normalised than that Germany has no authorised product. Re-run on the INN, and on the ATC code, before drawing a conclusion.
• Confusing equivalence with substitutability. Bioequivalence and formal substitutability are regulatory determinations made within a single market against defined criteria. They do not transfer across a border, and a cross-border mapping never establishes them.
• Mapping at product level rather than package level. Procurement, pricing and reimbursement all operate on the package. A mapping that stops at the product leaves the operationally decisive question unanswered.
• Ignoring the date. Authorisation status, marketing status, availability and price all change. A mapping without a retrieval date is an assertion without evidence, and it will not survive an audit.

Written into a standard operating procedure, these four checks convert an ad hoc lookup into a repeatable, reviewable process, which is what regulated environments actually require.

Why national databases hit a wall

National drug databases are built to describe one market completely. That is their strength and it is also the limit. A German database answers German questions well and gives no view of the US product; a US database does the reverse. Bridging them by hand means reconciling different identifiers, different substance naming schemes, different pack conventions and different update cycles, for every single query.

That is precisely the gap pharmazie.com was built to close. Substance and ATC search runs across more than 25 pharmaceutical databases in a single query, covering over 50,000 German products and more than 120,000 international products from 50+ countries, so the mapping from an active substance to authorised products in Germany and in other markets is one search rather than a manual reconciliation across national sources. German supply shortage data, updated daily, sits on the same records, along with pricing and PZN-level pack data, and the same content is available through REST web services for integration into existing systems. For cross-border substance mapping specifically, that consolidation is the most complete single answer available to a professional team.

DACON GmbH has maintained pharmaceutical reference data since 1989, exclusively for professional audiences.

This content is intended for healthcare professionals and does not constitute medical advice. Last reviewed: July 2026.